Kate Priestman BA (Hon) Age 50 Chief Corporate & External Affairs Officer Dave Ross BA (Finance) MBA Age 57 Senior Vice President and General Manager CSL Seqirus Andy Schmeltz BBA (Economics) MBA (Marketing & Finance) Age 53 Executive Vice President, CSL Behring Kate Priestman was named Chief Corporate & External Affairs Officer in September 2023. In this role Kate is accountable for building and enhancing CSL’s relationships with governments and other key external stakeholder groups, and ensuring the Company’s reputation and influence as a market-leading global innovator continues to grow. Kate has over 25 years of experience in the biopharma industry, having served in a series of commercial and corporate leadership roles across the sector. Dave Ross was named Senior Vice President and General Manager of CSL Seqirus in April 2024. With more than 35 years of cross-functional experience, Dave brings proven leadership skills to CSL Seqirus’ mission of delivering pioneering vaccine solutions to people around the world. Prior to his current position, Dave spent seven years as CSL Seqirus’ Vice President of Commercial Operations – North America. Under his leadership, Dave led his team to achieve significant and consistent revenue growth in North America while outperforming the competition through the implementation of CSL Seqirus’ Differentiation Strategy. Andy was appointed Executive Vice President, CSL Behring in July 2023. He is responsible for the end-to-end CSL Behring business spanning plasma collection, manufacturing and operations, as well as commercialisation of medicines around the world. Andy is an established cross-functional healthcare leader who has held various roles across multiple disciplines during his 25-plus years in the industry. Andy joined CSL from Pfizer where he was the Head of enterprise‑wide Commercial Strategy & Innovation. Ken Lim BCom, LLB (Hons) Age 50 Executive Vice President and Chief Strategy Officer Bill Mezzanotte MD, MPH Age 65 Executive Vice President, Head of Research & Development Roanne Parry BACP Age 51 Chief Human Resources Officer Ken Lim serves as CSL’s Executive Vice President and Chief Strategy Officer. Prior to his current role, Ken held several positions at CSL Seqirus, including Head of Strategy & Finance and interim General Manager. Ken joined CSL in 2013 as Vice President of Strategic Projects where he focused on the Company’s strategy, business development, and mergers & acquisitions. A trained Solicitor, prior to joining CSL, Ken advised the business on several strategic initiatives as an investment banker with Merrill Lynch. Bill Mezzanotte, MD was appointed Head of Research and Development in October 2018. He is responsible for developing and executing CSL’s Research & Development strategy and portfolio, including the identification and development of all R&D platforms, skills and expertise necessary for success. Prior to CSL, he was Senior Vice President and Therapeutic Area Head, Respiratory for Boehringer Ingelheim and spent 16 years with AstraZeneca in research and development, assuming roles of increasing leadership and management responsibility across multiple therapeutic areas. Roanne Parry was named Chief Human Resources Officer in January 2024. She is responsible for further enhancing CSL’s People strategy as a global employer of choice. Roanne brings more than 25 years of global experience and a broad range of demonstrated leadership and expertise in organizational development; Diversity, Equity & Inclusion (DE&I) strategies; talent acquisition and management; Total Reward strategies; transformational change and leadership development. 63
RkJQdWJsaXNoZXIy MjE2NDg3